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ABSTRACT
Transcripts containing premature termination
codons (PTCs) can be subject to nonsense-
associated alternative splicing (NAS). Two models
have been evoked to explain this, scanning and
splice motif disruption. The latter postulates that
exonic cis motifs, such as exonic splice enhancers
(ESEs), are disrupted by nonsense mutations. We
employ genome-wide transcriptomic and k-mer
enrichment methods to scrutinize this model. First,
we show that ESEs are prone to disruptive non-
sense mutations owing to their purine richness and
paucity of TGA, TAA and TAG. The motif model
correctly predicts that NAS rates should be low
(we estimate 5–30%) and approximately in line
with estimates for the rate at which random point
mutations disrupt splicing (8–20%). Further, we
find that, as expected, NAS-associated PTCs are
predictable from nucleotide-based machine learning
approaches to predict splice disruption and, at
least for pathogenic variants, are enriched in ESEs.
Finally, we find that both in and out of frame muta-
tions to TAA, TGA or TAG are associated with exon
skipping. While a higher relative frequency of such
skip-inducing mutations in-frame than out of frame
lends some credence to the scanning model, these
results reinforce the importance of considering
splice motif modulation to understand the etiology
of PTC-associated disease.
INTRODUCTION
Understanding the molecular mechanisms that underpin
genetic diseases is core to genetic-based medicine (e.g. see
(1–3)). Nonsense mutations, generating in-frame premature
termination codons (PTCs), are disproportionately com-
mon as a cause of genetic disease accounting for around
11.5% of human inherited diseases (4,5). PTC pathogenic-
ity is often assumed to be owing to one of two well-
described mechanisms. First, a PTC may result in the syn-
thesis of a truncated protein with potentially problematic
loss of function or gain of toxicity (5–7). Second, nonsense-
mediated decay (NMD) (8,9) targets some PTC-containing
transcripts for degradation, potentially avoiding any toxic
effects of truncated proteins in heterozygotes, but largely
abolishing expression in PTC homozygotes.
There is, however, at least one further possibility (10), re-
ferred to as nonsense-associated altered splicing (NAS) (11–
13). Just as synonymous and nonsynonymous mutations
can cause disease by altering splicing (14,15), so too PTC-
containing exons can cause exon skipping (reviewed in 15).
With the PTC bearing exon removed, the PTC in question
is hence not subject to NMD (N.B. as PTCs are usually de-
fined at the DNA level under an assumption of canonical
splicing, we retain the language of PTCs even if they induce
exon skipping).
Skipping of PTC-containing exons can reduce the impact
of the PTC if the skipped exon is a multiple of three long (see
e.g. 16,17–19) but can also be associated with pathogenic-
ity (see e.g. 20,21–24). Removal of an exon may itself be
catastrophic enough to cause disease, even if the exon is a
multiple of three long. If the exon skipped is not a multi-
ple of three long, skipping as a result of NAS would in-
troduce a frameshift with the usual deleterious knock-on
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consequences (novel peptide, downstream PTCs or read-
through to the poly A tail).
The mechanism of NAS is unresolved with at least two
non-mutually exclusive models being proposed, scanning
and motif disruption (for review, see 11,15). The scanning
model (25,26) evokes a mechanism that somehow verifies
the integrity of an ORF and, when necessary, directs the
splicing machinery to skip (or otherwise disrupt the splic-
ing of) the offending exon (reveiwed in 15). Exactly how a
nonsense mutation leads to splice disruption in this model
is not so clear. One version of the model (25) proposes
there to be a machinery for the detection of the PTC via
a translation-like scanning mechanism in the nucleus (for
review, see 15), potentially comparable with nuclear scan-
ning associated with NMD (27). Although contentious, ev-
idence suggests that both a translation-like mechanism (28–
31) and NMD (12) are observed in the nucleus, implying
the presence of active ribosomes that could detect PTCs
prior to nuclear export. Evidence for coupled transcription
and translation in mammalian nuclei (31) adds credence
to the possibility of a mechanism permitting translational
feedback to co-transcriptional splicing. Other models sug-
gest cytoplasmic scanning via conventional ribosomes with
some mode of feedback to splicing (for discussion see 32).
Here, PTC recognition occurs during the process of cyto-
plasmic translation that then acts in trans to increase pro-
duction of the PTC-free alternatively spliced mRNA. How-
ever, how such feedback might occur in a manner that is
allele-specific and isoform-specific is far from clear (32).
No matter what the possible mechanism, a defined read-
ing frame is a prerequisite of scanning models (33). Consis-
tent with this, all three nonsense mutations in exon 51 of the
FBN1 gene disrupt splicing but regular splicing is restored
by introducing frameshifts upstream of the nonsense vari-
ant (26) (see also 34,35–37).
Frame dependency has, however, been questioned in
some claimed incidences (38), a motif disruption model be-
ing argued to be more parsimonious (39). This model sug-
gests that NAS-causing nonsense mutations modulate im-
portant splicing regulatory motifs within immature mRNA
(11,12). A priori nonsense mutations might be more likely
than many to disrupt CDS exonic splicing motifs, as such
motifs are likely to have an especially low density of stop
codons (40) owing to the fact that they are embedded within
coding sequence (CDS) (40), which by definition cannot
have TGA, TAA or TAG in at least one frame. Indeed, ex-
onic motifs associated with RNA binding proteins typically
have a low density of stop codons (40).
In this context, exonic splice enhancers (ESEs) are strong
candidates for motifs that might be disrupted by nonsense
mutations. ESEs are purine rich motifs that function by
binding serine-arginine rich (SR) proteins that in turn di-
rect the splicing machinery to the splice junction and facil-
itate the assembly of the spliceosome (41). Mutational dis-
ruption of ESEs resulting in incorrect splicing is well de-
scribed (11,22,42–47) and ESEs are especially abundant at
exon ends (48), the terminal ≈ 70bp (48), where splice dis-
rupting mutations are most common (49). ESEs may also
exist in a sequence space that is especially prone to disrup-
tive nonsense mutations. Despite the purine enrichment of
both ESEs and stop codons, ESEs have a low density of
TAA, TGA and TAG motifs (40) (see also 50). This may
well reflect the fact that, while such motifs need only avoid
nonsense mutations in one frame, they tend to be employed
in all frames (51). ESEs then may well have a high rate of
gain of nonsense mutations owing to purine richness, while
the same nonsense mutations are likely to destroy the ESE,
owing to ESE being in CDS and hence having a low TGA,
TAA or TAG density.
The motif disruption model presumes that a point mu-
tation that disrupts the motif can be of large enough effect
to make meaningful differences to splice patterns. This is
supported by population genetic and molecular evolution-
ary analyses (48,52–57), by individual case histories (see for
review 15,41) and by minigene random mutagenesis experi-
ments (for meta-analysis see 58). Such point mutations are
known to be causative of genetic disease (see, e.g. 20,59,60–
63). Recent population genetic evidence also indicates that
selection on ESE disrupting mutations is commonly strong
selection (56). PTCs disrupting ESEs causing NAS have
been described (see, e.g. 11,42,43,45,64). Evidence for se-
lection against TAA, TAG and TGA in non-coding tran-
scripts (lncRNAs) owing to selection for ESEs (40), pro-
vides further evidence that mutation to these trinucleotides
disrupts splicing owing to motif disruption independent of
translation (presuming that lncRNAs are not affected by
translationally-mediated mechanisms).
While to date NAS has been analysed via close scrutiny of
individual examples (for review see 15), here we aim to add
to this literature a genome-wide survey. In particular, we
scrutinize the motif model as it makes predictions that are
approachable by such an approach. We consider three such
predictions. First, the model predicts that only some PTCs
would cause skipping and, in turn, that rates at which PTCs
disturb splicing should be on a par (or slightly higher) than
seen for random (non PTC) mutations. Meta-analysis of
random mutagenesis experiments involving minigene con-
structs suggest that on average, allowing for the biased small
size of the experimental minigene exons, 8–21% of exonic
point mutations disrupt splicing (58). Hence, if nonsense
mutations are like any mutations that modulate motifs, then
we might expect a similar proportion to also affect splic-
ing. Given that stop codons are depleted in exonic motifs
(40), including ESEs (40), the frequency of PTCs that mod-
ulate splicing might be expected to be at the upper end of
the range seen for random mutations. However, the various
estimates for the frequency of splice-disrupting mutations
(including ours) are not meaningful at that level of resolu-
tion, so we do not broach this issue. We do however, ask
whether nonsense mutations are more likely to be associ-
ated with skipping than comparable mutations. Second, the
motif disruption model predicts which PTCs should (and
should not) disrupt splicing. Specifically, the motif model
predicts that the PTCs that disrupt splicing are dispropor-
tionately embedded in exonic motifs that affect splicing.
Third, the motif disruption model predicts that mutations
generating the trinucleotides TAA, TGA or TAG in any
frame should disrupt splicing as the motifs themselves are
frame independent (51).
To address the first prediction, we provide rough esti-
mates for the commonality of PTCs disrupting splicing. We
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estimates. To generate a lower bound, we consider the non-
disease-associated context via 1000 Genomes data (65) cou-
pled with associated transcriptomics to detect exon skip-
ping associated with PTCs. Note that here we focus on
exon skipping alone both because it is the splice disrup-
tion mode most reliably detected from the available tran-
scriptomics and because this is the most common mode of
splice disruption in wild type state in humans (66), in re-
sponse to mutation (67) and associated with CRISPR gen-
erated indels (68,69). We use a minigene construct to ex-
perimentally validate our top NAS candidate (but not to
arbitrate on the mechanism). As purifying selection would
most likely have removed highly deleterious alleles from the
sampled populations prior to analysis, any PTC present in
this data is likely not to have major effects. Hence these
data most likely under-estimate rates at which de novo PTCs
are associated with splice disruption. Indeed, a reduced fre-
quency of SNPs at functional ESEs is central to the logic of
frequency-based motif confirmation analyses (48). The po-
tential deleterious effects of the PTCs that are observed in
such data may be buffered by some means, possibly owing to
heterozygosity.
To consider the upper bound, we consider PTCs in the
disease-associated context via ClinVar data (70). We expect
the frequency of nonsense mutations resulting in NAS to be
higher in disease-associated contexts than in non-disease-
associated contexts owing to the opposite ascertainment bi-
ases. Here we employ an estimation methodology based on
enrichment of residues towards exon ends (62,71), splice-
disrupting mutations being enriched at ends (48,49). This
enrichment analysis is a special case of exon k-mer enrich-
ment analysis that is an experimentally validated means to
identify splice associated motifs (e.g. 62).
To test the second prediction, we ask whether machine
learning models that successfully predict splicing from nu-
cleotide content alone (72) correctly predict which PTCs
disrupt splicing the most, as estimated from 1000 Genomes
data. As these approaches are ‘blind’ to the underlying
mechanism, we also consider specifically whether PTCs are
enriched in well-described exonic splicing motifs. For this,
we employ ESEs as these are the best-defined exonic splice
motifs, with four large scale analyses enabling definition of
hexamers that all, or nearly all, analyses agree to be ESEs
(52). To examine the third prediction, we employ the same
resources as we employed to determine the lower bound
estimate (i.e. 1000 genome data with coupled transcrip-
tomics). We estimate the rate at which out-of-frame muta-
tions to TAA, TGA or TAG are also associated with exon
skipping. We start by showing that ESEs do indeed sit in
an unusual place in sequence space that renders them espe-
cially likely to have a high rate of nonsense mutations that
in turn break ESE functionality.
MATERIALS AND METHODS
Data sources
All analyses were performed using the reference genome
sequence and annotations for GRCh37, Ensembl release
87 (73) (http://ftp.ensembl.org/; last accessed 25 January
2018). Polymorphism data was retrieved from the EBI
1000Genomes FTP site (65) (ftp://ftp.1000genomes.ebi.ac.
uk/vol1/ftp/, last accessed 24 January 2018). BAM files
containing GEM-aligned RNA-seq data for individuals
from the 1000 Genomes project were retrieved from the
EBI FTP site (74) (http://ftp.ebi.ac.uk/, last accessed 8
February 2018). Only samples present in both datasets
were retained. Bam files for the second RNA-seq dataset
were downloaded from Array Express (https://www.ebi.
ac.uk/arrayexpress/experiments/E-GEOD-19480/, last ac-
cessed 25 March 2020). Protein family data was down-
loaded from Ensembl Biomart (75) (http://grch37.ensembl.
org/biomart, last accessed 12 February 2018). ClinVar data
containing information regarding disease associated muta-
tions was downloaded from the NCBI FTP site (70) (ftp:
//ftp.ncbi.nlm.nih.gov/pub/clinvar/, last accessed 11 May
2018). INT3 ESE motifs were retrieved from the supple-
mentary data to Caceres and Hurst (52).
General methods
Custom Python 3.6.4 scripts were used for all data handling
and are available at http://github.com/rosinaSav/NAS code,
including the use of standard Python modules, as well as
NumPy v1.91 (76). Data plotting and statistical analyses
were performed using R v3.2.1 (77). BEDTools v2.27.1 was
used for operations on genome coordinates (78). SAMTools
v1.7 was used for BAM file manipulation (79). VCFtools
v0.1.15 (80) and tabix v0.2.5 (81) were used to perform op-
erations on SNP data. STAR aligner v2.7 was used to align
raw reads from the E-GEOD-19480 dataset (82).
Analysis of the frequency of nonsense mutations in ESEs
We consider all possible mutations at all possible sites
within the INT3 set of hexamers (52) asking whether the
mutation would generate an in-frame stop codon where
there was none before and if the resulting hexamer is not
in turn identified as an ESE within the INT3 list. Specif-
ically, if any given mutation generated a stop codon (in
any frame) then this was considered a candidate nonsense
mutation. However, in some instances the location of the
new stop was an old stop in the original hexamer. For
example, TGAAGA is one of the 84 INT3 motifs and a
G→A mutation at position 2 generates a new TAA codon
(TGAAGA→TAAAGA). In this case, as the original TGA
could not have been in-frame this could not be a nonsense
mutation and so was excluded. Similarly, if the first trin-
ucleotide is a stop codon then the following trinucleotide
cannot also be an in frame nonsense mutation and so was
ignored (ie TGAAGA→TGATGA were not considered).
Comparably, if the second full codon (residues 4–6) is a stop
codon then the first three cannot mutate to an in-frame stop
and so these too were not considered. We thus preserved all
changes that were from a coding nucleotide, were the frame
appropriate, to a stop codon. Significance was determined
by repeated sampling of 84 randomly chosen hexamers from
concatenation of the full human RefSeq CDS dataset. Each
simulant was analysed using the same rules and the number
of nonsense mutations determined. P was given and n/m,
where n is the number of simulants with as many or more
nonsense mutations as in the real data and m is the number
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Compilation of protein-coding exon set
The main open reading frame (ORF) for protein-coding
genes was extracted from the genome annotations. Se-
quences were filtered to include only those that had canon-
ical start and stop codons, only contained canonical nu-
cleotides, were of a length that is a multiple of three and
did not include premature stop codons. Only the transcript
isoform with the longest ORF was retained for each of the
genes. In order to preserve data independence, only a single
gene was retained from each Ensembl protein family, one
being selected at random. Finally, the internal fully coding
exons that did not overlap other annotated exons were ex-
tracted. This filtered set of exons was used for all analyses.
SNP filtering
SNPs for individuals were intersected with the set of coding
exons to obtain all SNPs within the samples. From these,
their relative positions within the exon and CDS were cal-
culated. The mutation status of each SNP (e.g. ‘nonsense’
or ‘missense’) was determined with custom Python code us-
ing this positional data, and the reference and variant alle-
les. While focal analysis considers only SNPs that generated
PTCs, we also consider out of frame mutations to TGA,
TAG and TGA as well as ‘matching’ non-nonsense muta-
tions to compare with the nonsense ones. Note that in the
rare event of multiple PTCs being identified in any given
exon, to avoid pseudo-replication of data, the exon was con-
sidered only once and one PTC selected at random for con-
textual analysis. This left 1180 PTCs.
Quantification of splice isoforms
GEM-mapped reads from the Geuvadis BAM files were
subject to quality filtering as per the protocol in (74). Briefly,
reads were filtered to uniquely mapped reads with a base
mapping quality scale between 251 and 255 or 175 and
181 inclusive. Further, only reads with no more than six
mismatches were included. These reads were then mapped
to the exon-exon junctions that flank the exons in our
dataset.
For each exon and each individual, we counted the num-
ber of reads that supported inclusion by counting those
that mapped to the exon-exon junction between the focal
exon and either of the two flanking exons as defined by En-
sembl annotations. Similarly, we counted reads supporting
skipping by counting the number of reads that mapped to
the junction between the two exons flanking the focal exon.
The number of reads supporting exon skipping was multi-
plied by two, as these reads can only map to a single exon-
exon junction, whereas reads that support exon inclusion
can overlap either of two exon-exon junctions.
Read counts were then used to calculate several metrics
for each exon in each sample: PSI, RPMinclude and RPM-
skip. PSI is defined as the number of reads containing the
exon, divided by the number of reads containing the exon
plus the number of reads where the exon is skipped. PSI
(PSIPTC−/+ − PSIPTC−/−) is used to describe the PSI differ-
ence between the two genotypes for each exon. If there is less
exon inclusion when a PTC is present (i.e. lower PSI and in-
creased exon skipping), PSI is negative. We are aware that
this custom method for estimating PSI is imperfect, as it
may lead to incorrect inferences in the case of splicing aber-
rations other than exon skipping. However, we could not
use existing packages for calculating PSI as our analysis re-
quired a metric that could be easily modified to account for
the confound of NMD (see below). Exon skipping accounts
for the majority of alternative splicing events in humans
(66). Therefore, the noise introduced by the imperfections
in the method is expected to be small.
RPMinclude is defined as the number of reads con-
taining the exon divided by the total number of reads in
the sample. RPMskip is defined as the number of reads
without the exon divided by the total number of reads in
the sample. Accordingly, RPMincl (RPMincludePTC−/+
− RPMincludePTC−/−) and RPMskip (RPMskipPTC−/+
− RPMskipPTC−/−) then describe the differences between
PTC−/+ and PTC−/− variants for RPMinclude and
RPMskip, respectively.
For RPMinclude and RPMskip, the total number of
reads remaining after quality filtering of the BAM files is
included in the calculation to account for differences in
both sequencing depth and read quality between samples.
We therefore first determined the total read count. We then
filtered the BAM file to only contain reads overlapping
our exon-exon junctions. We performed the quality filter-
ing on these exon-exon junction reads and sampled the read
count. The proportional decrease between the non-quality
filtered exon-exon junction reads and quality filtered exon-
exon junction reads was then used to scale the initial read
count to estimate the number of total reads after quality fil-
tering. We find no significant difference (P = 0.188, paired
Wilcoxon signed-rank test) between the proportion of reads
retained after filtering the full BAM file and after filtering
after intersection with exon−exon junctions, arguing that
applying the proportional decrease for exon-exon junctions
to the full read count is unbiased and appropriate (see Sup-
plementary Figure S1).
Further filtering of candidates
1,180 exons were found to contain a PTC in some but not all
individuals, allowing for comparison between the different
genotypes. Before calculating the metrics described above,
we excluded those exons for which less than half of the indi-
viduals (with or without the PTC) presented reads mapping
to the relevant exon-exon junctions. This was so as to avoid
drawing unreliable conclusions based on data from only a
small number of individuals.
We also required at least one of the remaining individuals
to contain a PTC in the exon (otherwise skipping could not
be evaluated) but did no further filtering based on the num-
ber of exons within each genotype (PTC+/+, PTC−/− or
PTC+/−). This is because by imposing a higher threshold
for the minimum number of PTC-containing individuals,
we would have biased our selection against the more dele-
terious PTCs, which are expected to be rare. However, our
removal of exons where only a minority of the individuals
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ing lowly expressed genes. Hence, inferences drawn based
on the remaining set are expected to be less sensitive to the
number of individuals that they are based on.
In addition, we retained only constitutive exons, defined
as exons present in all annotated transcript isoforms. The
advantages of this approach are two-fold. First by avoiding
noise associated with variable exon skipping in PTC−/−
condition the confidence that can be ascribed to any given
calls of exon skipping increases. Second, even if skipping
rates were perfectly deterministic (not noisy), as native skip-
ping rates go up (i.e. PSI tends to zero), the parameter space
within which further skipping can be resolved becomes ever
more restricted (at a hypothetical limit of PSI = 0, there can
be no further reduction). Thus consideration of exons that
appear constitutive renders resolution of changes to rates
of skipping, but not of inclusion, maximally robust. This
left N = 541 PTC-containing exons (for metadata on these
exons see Supplementary data S1, for sequences see Supple-
mentary data S2).
Missense mutation simulations
We performed 100 simulations in which each of the real
PTCs was randomly matched to a missense mutation. For
each PTC, the missense mutation was sampled in order to
match the PTC’s ancestral allele identity, variant allele iden-
tity and variant allele frequency (to a precision of 0.05).
The same analyses were then performed on the sets of pseu-
doPTCs (pPTCs). To further control for distance to exon
boundary, we calculated the relative PTC position as the
distance to the 5′ exon end. We then defined a window of five
nucleotides to either side of this position and selected pseu-
doPTCs whose relative position within the exon in which
they were found was within this window. If none were avail-
able, the window was increased by one nucleotide until a
suitable simulant was identified or 10 window expansions
had occurred, whichever happened first.
Minigene constructs
A minigene construct for ACP1 (ENST00000272065) was
ordered from GeneArt as a double-stranded DNA string
subcloned into the Gateway-entry vector pENTR221. The
minigene consisted of the 5′ flanking exon, 5′ flanking in-
tron, focal exon, 3′ flanking intron and 3′ flanking exon (see
Supplementary Spreadsheet S5 for sequence information).
Two versions were designed: one in which the wild-type se-
quence of the focal exon is preserved (‘wt’) and one con-
taining the PTC-causing mutation (‘PTC’). To allow these
genes to be translated, a start codon (ATG) was added at
the 5′ end of all sequences. The 3′ flanking exon is the final
exon and therefore already contains a stop codon (TGA).
All minigenes were subcloned into pCM3, a Gateway-
compatible CMV-driven mammalian expression vector (de-
scribed in (83)), using Gateway LR Clonase II enzyme mix
(Thermo Fisher) according to manufacturer’s instructions.
pCM3 additionally also drives the constitutive expression
of mKate2 from an independent expression cassette which
allows to correct for technical variability in transfection ef-
ficiency. The control NMD reporter constructs of human
TCR- have been previously described (84).
Plasmid and siRNA transfections
HeLa and Hek293T cells were maintained in DMEM
(Gibco) supplemented with 10% fetal calf serum (FCS) at
37◦C, 5% CO2. NMD knockdown experiments were per-
formed by two rounds of consecutive transfections with
siRNA targeting Upf1 (sihUPF1-I: GAGAAUCGCCUA
CUUCACU (+UU) and sihUPF1-II: GAUGCAGUUC
CGCUCCAUU (+UU), Dharmacon, mixed in equimolar
ratio). As a negative control, cells were transfected with
a non-targeting control siRNA (ON-TARGETplus Non-
targeting Control Pool, Dharmacon). In brief, cells were
grown to 40% confluency in 12-well plates before trans-
fecting with 1.25 l of 20 M siRNA stocks using 5l
Dharmafect1 transfection reagent (Dharmacon). After 48
h, the siRNA transfection was repeated using Lipofec-
tamine 2000 transfection reagent instead (Thermo Fisher)
and with the addition of 100ng of pCM3 plasmid carrying
the minigenes. Cells were grown for a further 48hrs before
harvesting.
RNA extraction and RT-PCR analysis
RNA from transfected cells (3 biological replicates for
each condition) was extracted using the Qiagen RNAeasy
kit according to manufacturer’s instructions, including the
on-column DNase I digest step. cDNA synthesis was
performed using SuperScript III Reverse Transcriptase
(Thermo Fisher) with 1g of RNA and using 500ng an-
chored oligo(dT)20 primers (Thermo Fisher). cDNA was
further treated with 5U RNAse H (NEB) before dilut-
ing with 30l nuclease-free water. 2l of each cDNA di-
lution were used as template in PCR reactions using ei-
ther AccuPrime Pfx DNA polymerase (Life Technologies;
ACP1 and mKate2 for HeLa samples) or Taq DNA poly-
merase (Life Technologies; ACP1 and mKate2 for Hek293T
samples) following manufacturer’s recommendations and
0.3 M of gene-specific primers (for primer sequences see
Supplementary Spreadsheet S6), ensuring amplification is
within the exponential range. For quantitative Real-time
PCR measurements of Upf1 and TCR expression, samples
were analysed in triplicate reactions on a Roche LightCy-
cler480 using Roche LightCycler480 SYBR Green I Mas-
ter Mix. Relative expression levels were determined using
the Comparative Ct method (85) and normalised against
GAPDH levels. ACP1 and mKate2 PCR products were re-
solved on 1.5% agarose in TBE gels stained with Ethidium
bromide and imaged on a Syngene U:Genius 3 gel imager.
Bands were quantified via densitometry with background
subtraction using Image Studio Lite (v5.2). The resulting
signals from ACP1 bands were further normalised to the
signal of mKate2 bands from the same respective cDNA to
account for technical variability in transfection efficiency.
PSI was calculated as before, using the normalised signal
of full-length transcript divided by the normalised signal
of full-length transcript plus the normalized signal of tran-
script with skipped exon. Relative exon skipping was cal-
culated by dividing the normalised signal of transcript with
skipped exon of any given condition by the normalised sig-
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Out of frame PTCs analysis
For the out of frame PTC analysis, when determining the
SNP type (synonymous, missense, nonsense), we shifted the
reading frame forwards and backwards by one nucleotide.
As a result, if the three nucleotides starting from the shifted
codon position encoded a stop codon, we called this a PTC.
We then repeated the pipeline with shifted PTCs.
ClinVar analyses
Disease-associated mutations were downloaded from the
ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/,
last accessed May 11 2018; (86)) and intersected with the
filtered exon set to leave only SNPs that occurred in our
coding exons (N = 156,730). We then verified the status
of the disease-associated mutations, retaining only those
labelled ‘pathogenic’ or ‘likely-pathogenic’ (although note
that this classification is at the discretion of the submitters
and hence not standardised). The mutation status of each
SNP was then verified. N = 23 092 synonymous and non-
synonymous variants were retained for ensuring these vari-
ants were not used in the reference allele-matched simula-
tions and for determining the exons in which they reside
for exon comparisons. Nonsense mutations were intersected
with the 1000 Genomes dataset and only the N = 7429
non-overlapping nonsense variants retained. This results
in N = 6354 ‘pathogenic’ and N = 1075 ‘likely pathogenic’
variants.
Splice variant prediction
PTC variants were analysed using MMsplice (72), a
neural network model trained on large-scale genomics
datasets to predict the effects of variants on exon skipping,
splice site choice, splicing efficiency and pathogenic-
ity. Variants were compiled into a single VCF file with
effects predicted using the model default parameters
(exon cut l = 0, exon cut r = 0, acceptor intron cut = 6,
donor intron cut = 6, acceptor intron len = 50,
acceptor exon len = 3, donor exon len = 5,
donor intron len = 13, split seq = False). Changes in
exon inclusion are reported as mmsplice dlogitPsi values,
with negative values indicating a predicted increase in
exon skipping (lower PSI) and positive values indicating a
predicted decrease in exon skipping (greater PSI) due to
the variant.
Expression analysis
We used FANTOM5 data (87) to estimate expression pa-
rameters independently of the Geuvadis RNA-seq data that
was used to analyse splice isoforms. We retrieved the phase
1 and 2 combined normalized .osc file from the FANTOM5
website (http://fantom.gsc.riken.jp/5/datafiles; last accessed
11 February 2016). We only retained samples where the
name contained the string adult, pool1. All brain tissues ex-
cept for the full brain sample and the retinal sample were re-
moved to avoid redundancy. For each gene included in our
analysis, we defined a region of 1001 base pairs centred on
the start coordinate of the Ensembl transcript annotation
as the promoter and associated all peaks that overlapped
that promoter to that peak. If several peaks were associ-
ated to a single transcript, we summed the transcripts per
million (TPM) within each sample across the peaks. A gene
was considered to be expressed in a given tissue if TPM > 5.
RESULTS
Evidence that ESEs should be hotspots for disruptive non-
sense mutations
Prior to examining predictions of the motif model, we start
by asking whether ESEs are a priori likely to be hotspots for
nonsense mutations that would disrupt splicing (i.e. break
an ESE). As we previously noted, like other exonic motifs
ESEs have a dearth of the trinucleotides TGA, TAA and
TAG (40). Importantly, like these three codons, ESEs are
also purine rich (52). These two features place ESEs in an
unusual position in hexameric sequence space: they are ex-
pected to have a high rate of gain of nonsense mutations
(owing to purine richness), while the same nonsense muta-
tions are likely to destroy the ESE (owing to the rarity of
nonsense mutations in CDS based motifs).
To consider this hypothesis more formally, we consider
the INT3 set of 84 hexamers, this being a set of ESE hexam-
ers found in at least three of four large scale surveys (52). We
consider all possible mutations at all possible sites within
the hexamers asking whether the mutation would gener-
ate a stop codon where there was none before (see Mate-
rials and Methods). There are 219 such nonsense mutations
within the 84 INT3 ESEs. We next checked whether the
new nonsense containing hexamer is a known INT3 hex-
amer. For example, TCAAGA→TGAAGA reflects an ESE
transitioning to another ESE via a nonsense mutation, both
hexamers featuring in the INT3 set. After elimination of all
such instances 204 instances remain where an ESE becomes
non-ESE (or at least aren’t in the INT3 set) owing to a non-
sense mutation.
To determine whether 204 is an unusually high number,
we repeated the same analysis but this time with 10 000 data
sets of 84 pseudo-ESEs as the input data set. As we are in-
terested in the hypothesis that ESEs have a higher rate of be-
ing broken by nonsense mutations than random sequences
within CDS, we randomly selected 84 non-redundant hex-
americ sequences from CDS of human RefSeq genes. For
each set of 84 hexameric pseudo-ESEs we then apply the
same protocol as above, this time asking whether the non-
sense containing mutated pseudo-ESE also features in the
relevant pseudo-ESE hexameric list. From 10 000 simula-
tions we find no simulation that has 204 or more nonsense
mutations that move the hexamer from the pseudo ESE list
to the non-pseudo ESE list (mean in randomized set = 131
± 11.4 SD, max = 184). We conclude that compared to ran-
dom CDS, ESEs are indeed especially prone to being the
site of a nonsense mutation that breaks the ESE (from the
above simulation, P < 0.0001).
To check that in part the result is owing to purine enrich-
ment, for each hexamer in the INT3 list we randomly ex-
tracted a hexamer from the concatenated CDS that had the
same total purine content and that wasn’t in the set of INT3
hexamers. We thus generated 10 000 random sets of 84 ex-
actly purine matched randomised sets. Repeating the analy-
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mutations (P = 0.004), but not by as great a difference as be-
fore (for purine matched randomised sets mean = 170, ± 9.9
sd, max = 208). The purine matched set has significantly
more opportunities for nonsense mutations than random
CDS hexamers (from simulation, P < 0.0001), as would be
expected given the purine richness of stop codons.
Part of the reason for the non-equivalence between the
purine matched set and INT3 in nonsense mutation rate is
likely to be a difference in stop codon density. Every in-
stance of a stop codon in any frame in a hexamer repre-
sents a codon where a nonsense mutation cannot happen
by definition and, in addition, increases the chances that
a nonsense mutation in a different hexamer within the de-
fined list generates a hexamer in the same defined list. In
the INT3 set of 84 × 4 = 336 full codons only nine are stop
codons (2.7%). By contrast, even in the purine matched con-
trols extracted from CDS, of the 10 000 84 pseudo-ESE sets
87% have more than nine stop codons (mean = 13 ± 3.12
sd). Indeed, if instead of purine matching, we randomize
the order of nucleotides in each hexamer (generating 10
000 sets of 84 shuffled hexamers in which each real hex-
amer is randomised once), then 98% of these sets have more
stop codons than INT3 (mean = 15, ±2.8 sd), emphasis-
ing just how lacking in stop codons INT3 is. Considering
the 596 purine-matched sets with exactly nine stop codons
in the 336 full codons we find these sets to be closer to
the INT3 set than the purine matched set (mean = 175 ±
8.43). That they still have fewer opportunities for nonsense
mutations than INT3 possibly reflects the skewed usage of
A over G within the purines and low T density (in INT3,
A = 46.6%, C = 11.7%, T = 9.9%, G = 31.7%). Indeed, con-
sidering the 119 hexameric sets of shuffled ESEs that also
have nine stop codons in the 336 possible codons (hence ex-
actly the same nucleotide content and the same stop codon
density as INT3), now we see no significant difference be-
tween INT3 and the randomised set (from randomisation,
P = 0.08, mean = 190, ±8.7, sd). Thus, the low stop codon
density and unusual nucleotide content, in part reflected as
skewed purine content, can in large part account for INT3
being especially prone to nonsense mutations that disrupt
ESE functionality.
Evidence that only a minority of PTCs are associated with
exon skipping
To address the predictions related to the commonality of
PTC-associated splice disruption and to establish a set of
PTCs that likely are (or are not) associated with NAS, we
started by assembling a set of 541 PTC-containing exons in
which we could quantify splicing (see Material and Meth-
ods, for summary of the 541 see Supplementary data S1).
For each exon, the median percentage spliced in (PSI) was
calculated (see Materials and Methods) for each of the three
genotypes: homozygous non-PTC (PTC−/−), heterozy-
gous PTC (PTC-/+) and homozygous PTC (PTC+/+).
We focus on comparisons between PTC−/− and PTC−/+
variants as only 24/541 (4.37%) exons had an individual
with a PTC +/+ variant.
We first asked whether there are detectable differences
in exon inclusion for the same exon as a function of PTC
presence. If PTCs are responsible for exon skipping, we ex-
pect the PSI for PTC−/+ variants to be lower than for
PTC−/− variants. This is also quite a generous test as we
employ exons annotated as constitutively included. Wild-
type PSI is thus expected to be close to 1 in the majority
of cases. As a consequence, when the PSI of the PTC−/+
genotype differs from that of the PTC−/−, it is more likely
to be decreased than increased, simply because PSI cannot
exceed 1. We find that PTC−/+ variants indeed have sig-
nificantly lower PSI than PTC−/− variants, although the
difference is small (mean PSI ≈ 0.960 and ≈ 0.977, respec-
tively; P = 1.056 × 10–5, two-tailed paired t-test) (see Fig-
ure 1A and Supplementary Figure S2A). Almost half of
the exons exhibit no difference in PSI between the geno-
types (PSI = 0, N = 239, 44.18%). In the majority of cases,
therefore, the presence of a PTC appears to have little to no
effect on skipping. However, a minority of cases do show
large, several-fold changes in the exclusion level of the exon
associated with the presence of a PTC (Figure 1A, left side
in the histogram). This is consistent with the motif disrup-
tion model of NAS, which predicts only a subset of PTCs
to lead to exon skipping.
PTCs are associated with effects beyond what is expected
given their nucleotide composition
Given that even by chance alone we expect a bias to nega-
tive PSI values due to the boundary at PSI = 1, we asked
whether nonsense mutations specifically are associated to
particularly large increases in exon skipping when com-
pared to other mutations. To account for nucleotide bi-
ases associated with mutations generating PTCs (see Sup-
plementary Text S1), we selected a control set of missense
mutations of similar nucleotide composition for compari-
son.
Specifically, for each PTC we simulated 100 pseudo-PTCs
(pPTCs) by randomly sampling missense mutations across
the genome matched by ancestral allele, variant allele and
variant allele frequency (e.g. if the total PTC count on both
alleles was 6/300, the matched mutation allele frequency
was ≈0.2). To quantify any difference in PSI, we calcu-
lated a Z score for each PTC, defined as the PSI for the
true PTC minus the mean of pseudo-PSIs (pPSI), di-
vided by the standard deviation of pPSI. Thus, if real
PTCs have a more negative effect on PSI than the matched
pPTCs as a result of being a PTC and not the nucleotides
involved, Z scores will be negative.
We find 308/541 (56.93%) PTCs have a Z score less
than zero, a small but significant deviation from null
(P = 7.213 × 10–4, one-tailed exact binomial test, Figure
1B). This suggests that nonsense mutations are more likely
to be associated with exon skipping than comparable muta-
tions that are not nonsense mutations. We can also control
for position by sampling a matched mutation from within
the 10 bp window around true nonsense variant location
(342/541 exons with Z < 0, P = 4.125 × 10–10, one-tailed ex-
act binomial test). Collectively these results imply that non-
sense mutations are special as regards exon skipping. These
results also suggest that the bounding of PSI between 0
and 1 is unlikely to explain entirely the association between
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Figure 1. Differences in relative exon skipping levels. (A) PSI scores for exons with non-zero differences in PSI between the two genotypes. PSI scores
corresponding to exons for which the PTC is associated with increased exon inclusion (PSI > 0) are typically small. For distribution see Supplementary
Figure S2A. (B) Z scores comparing the PSI score for each PTC with PSI scores for 100 missense mutations matched by ancestral allele, variant allele,
allele frequency and distance to exon boundary.
NMD cannot account for many cases of increased exon skip-
ping associated with a PTC
A possible alternative explanation for the association be-
tween PTCs and exon skipping is NMD, as it would remove
full length isoforms with the PTC, causing an increased pro-
portion of skipped reads, when in practice there has been
no change in the absolute skipping rate (see Supplementary
Text S2). It is therefore necessary to eliminate any PSI vari-
ations we observe that are also consistent with NMD. To
do this, we used the absolute read counts supporting exon
skipping or inclusion, normalised to the number of total
reads per million to control for differing read depths be-
tween samples (RPMskip and RPMinclude, see Materials
and Methods).
We first asked whether we could detect NMD. If so, the
raw number of reads supporting inclusion, RPMinclude,
should be significantly higher in PTC−/− than for PTC-/+
variants, i.e. RPMincl < 0 as full-length transcripts con-
taining a PTC are likely to be subject to NMD at some
rate. Our results suggest this is the case (P ≈ 2.648 × 10–7,
one-tailed paired t-test, Figure 2A), with the median RP-
Minclude for PTC−/+ variants (0.321) almost one third
less than the median RPMinclude for PTC−/− variants
(0.508).
If PTCs are associated with exon skipping, RPMskip
should be greater for PTC−/+ than for PTC−/− vari-
ants. PTC−/+ variants indeed have significantly higher
RPMskip values (P ≈ 0.019, one-tailed paired t-test; Fig-
ure 2B; Supplementary Figure S2B), however, as with PSI,
many cases have RPMskip = 0 (N = 239). Is the num-
ber of PTCs with raw read counts supporting greater skip-
ping for the PTC variant also higher than expected given
the nucleotide composition of PTC mutations? We reanal-
ysed the set of 100 matched missense simulants and asked
how many PTCs differ in RPMskip when compared
with simulant pseudo-RPMskip (pRPMskip) values.
A significant number, 339/541 (62.66%), have positive Z
scores (P = 0.004, one-tailed exact binomial test; note here
a positive Z score indicates increases in RPMskip over
the simulants). This result is robust to missense muta-
tions being matched by their distance to the exon bound-
ary (381/557, P < 2.2 × 10–16, one-tailed exact binomial
test).
These results suggest that the association between PTCs
and exon skipping cannot be explained solely by NMD, as
NMD should not affect the absolute count of reads that
support skipping.
Evidence that 6% of nonsense mutations may result in exon
skipping
The above results provide, to the best of our knowledge, the
first evidence of genome-wide associations between PTCs
and exon skipping. However, in most cases the effects are
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Figure 2. Differences in absolute skipping levels. (A) Raw read counts per million reads supporting exon inclusion (RPMinclude) for non-PTC and PTC
variants. 50 outlier data points are removed for visualisation purposes. (B) Non-zero RPMskip scores are consistent with those in the direction consistent
with NAS having larger effects. The median negative RPMskip is −4.794 × 10–4 arguing that when the PTC is associated with reduced exon skipping,
the effect is almost negligible. One data point for RPMskip < 0 at y = −0.759 and two outlier data points at for RPMskip > 0 at y = 1.242, y = 4.778
are omitted for visualisation purposes. For distribution see also Supplementary Figure S2B.
be biologically meaningful, in the sense that we may just be
witnessing experimental noise (see the clustering of values
around 0 in Supplementary Figure S2A). How frequently is
NAS associated with changes in PSI that are large enough
that they could be biologically meaningful?
While setting a threshold is to some degree arbitrary,
we suggest that a variant with a PSI > 5% or a change in
RPMskip > 0.026 (see Supplementary Text S3) will be un-
likely to be owing to noise and indicative of some mean-
ingful biology. A 5% figure is not entirely arbitrary as it is
both close to a turning point for statistical significance and
accords with recommended cut-offs when employing sim-
ilar data (88) (for fuller consideration see Supplementary
text S3 and Supplementary Figure S3). With such cut-offs,
50/541 (9.24%) exons show a large effect change in PSI, of
which 44 (88.00%) have PSI < 0 with many far exceeding
the 5% threshold Figure 3A). The direction of this enrich-
ment is highly significant (P = 1.662 × 10–8, one-tailed ex-
act binomial test). For RPMskip, we find 43/50 (86.00%)
large-effect cases have RPMskip > 0, indicating increased
exon skipping for the PTC−/+ variant (Figure 3B), signif-
icantly higher than expected by chance (P = 1.049 × 10–7,
one-tailed exact binomial test).
However, with caveats to both PSI (NMD effects) and
RPMskip (possible effects of differing transcript abun-
dances in the two differing genotypes) metrics, the most ro-
bust candidate exons with meaningful NAS-associated biol-
ogy are those overlapping both large-effect PSI and large-
effect RPMskip groups. 30 of the exons that appear in
both groupings show more exon skipping in the PTC−/+
genotype (Table 1). To ask whether this overlap is signifi-
cant, we performed 10,000 simulations picking 44 and 43
exons from the full set of PTC-containing exons (44 and
43 correspond to the number of exons with large NAS-
consistent effect sizes for PSI and RPMskip respectively).
We find no simulation iteration has an overlap as large as
the real overlap (P ≈ 9.999 × 10–5, one-tailed empirical P-
value, maximum simulant overlap = 10).
These PTCs are prime candidates for cases in which a
single nucleotide polymorphism (SNP) generating a PTC
causes potentially detrimental exon skipping via NAS. We
estimate that it is possible ≈ 6% (30/541) of annotated PTC
mutations cause NAS (these are annotated as ‘primes’ in
Supplementary data S1). Results using an alternative data
source produce a similar estimate (≈4%, Supplementary
Text S4), however we caution that this result is underpow-
ered.
Aside from the splicing characteristics, little differentiates
these 30 from the 511 remaining cases: there is no difference
in the size of the exon (t test, log exon size, P = 0.51) nor in
the distance of the stop codon from the nearest exon intron
boundary (P ∼ 0.429 from a two-tailed Welch’s t-test: Sup-
plementary Figure S4).
We also examined the rarer PTC+/+ instances (24/541).
Results are similar to those for PTC+/− variants, with PSI
values (median negative PSI = −11.920, median positive
PSI = 0.191) and RPMskip (median negative RPMskip
= −0.001, median positive RPMskip = 0.261) in the di-
rection consistent with NAS. However, given the limited
sample size we again caution against over-interpreting this
result. Note that all exons that had individuals with a +/+
genotype also had individuals with a +/− genotype. There-
fore, our decision not to include PTC homozygotes into
other analyses did not lead to the exclusion of any ex-
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Figure 3. Individual large effect cases for both PSI and RPMskip. Large differences between PTC−/− and PTC−/+ genotypes for (A) PSI and (B)
RPMskip. Variants with changes between genotypes consistent with NAS are in blue, those in the opposite direction in red. For both PSI and RPMskip,
the number of large-effect variants in the direction consistent with NAS is significantly greater than expected by chance.
No evidence for cis effects
It is possible that some PTCs are not causative of the splice
disruption that we observe but other cis-mutations in the
same exon are instead. This, we suggest, will have a very
minor relative effect on rate estimation, if any, as, of our
30 PTC candidates, 28 have no other SNP in the same
exon as that bearing the PTC. Moreover, of the other two
(ENST00000367409.18, ENST00000542534.16), the SNPs
identified were all common within 1000 Genomes data in-
dicating that it is unlikely that they are causative of the splic-
ing effect. ENST00000542534.16, for example, has one SNP
(15:42135988:C:T) in the exon that also bears the PTC but
this SNP is at a frequency of 76%. Were this causative, we
should have seen skipping at much higher rates. Altering the
thresholds for PTC calling will thus most probably provide
significantly more influence over the estimate of the lower
bounds than removal of exonic cis effects.
Experimental validation of the top NAS candidate
Having computationally identified potential NAS candi-
dates, we sought to validate our results experimentally.
Here, we do not intend to provide evidence as to the mecha-
nism, just to confirm that there is NMD-independent NAS,
as predicted by our bioinformatics pipeline.
A minigene construct for the prime candidate exon
from the ACP1 gene with the greatest RPMskip
(ENST00000272065.5, Table 1) was constructed and ex-
pressed as described in the Materials and Methods (Fig-
ure 4B). In HeLa cells, we find a significant difference
in PSI between the wt and PTC-containing constructs
(P = 2.226 × 10–5, two sample t-test, Figure 4A and B),
with skipping almost exclusively restricted to the PTC-
containing construct. Consistent with skipping resulting
from NAS and not NMD, this difference in PSI re-
mains after knockdown of the core NMD factor Upf1
(P = 2.783 × 10–8, two sample t-test, Figure 4B and C). As a
side note, the isoform with the PTC-containing exon is not a
significant target of NMD; if it were so, we would expect the
isoform to be more abundant in siUpf1 cells compared to
control cells, while we observe the isoform to be marginally
less abundant in the siUpf1 context (Figure 4B).
We also asked whether levels of the exon-skipped iso-
form significantly differ as expected were NAS the under-
lying cause. We find an increase in levels of the skipped
isoform with inclusion of the PTC (P = 1.804 × 10–4, two
sample t-test, Figure 4D) and again when NMD is knocked
down (P = 2.741 × 10–4, two sample t-Test, Figure 4D), sug-
gesting that the presence of the PTC results in an increase
in the absolute number of transcripts supporting skipping
regardless of NMD. Consistent with this notion, skipping
for PTC variants does not significantly differ between cells
where NMD is present or knocked down (P = 0.302, two
sample t-test, Figure 4D). We infer that NMD cannot ex-
plain the decreased exon inclusion associated with the PTC.
To confirm that NMD was depleted, levels of Upf1 mRNA
were quantified. We find that Upf1 mRNA levels are signif-
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Table 1. 30 prime NAS candidates
Exon ID PSI−/+ PTC−/− PSI RPMskip−/+ RPMskip−/− RPMskip logit
ENST00000272065.5 39.19 99.76 − 60.57 4.784 0.007 4.777 − 0.520
ENST00000325083.24 29.26 55.84 − 26.59 2.631 1.389 1.242 − 0.266
ENST00000271324.6 88.69 98.20 − 9.51 1.195 0.391 0.804 − 0.166
ENST00000400033.8 16.67 95.62 − 78.96 0.681 0.022 0.659 − 0.963
ENST00000216027.4 59.09 93.71 − 34.62 0.483 0.100 0.383 − 0.432
ENST00000359028.47 64.29 99.83 − 35.55 0.366 0.001 0.364 − 0.465
ENST00000367409.18 69.08 75.82 − 6.74 0.538 0.239 0.299 0.005
ENST00000267430.22 48.63 99.24 − 50.61 0.162 0.004 0.158 0.560
ENST00000288050.18 76.81 88.17 − 11.36 0.234 0.078 0.156 − 0.163
ENST00000456763.12 75.76 97.33 − 21.57 0.111 0.011 0.100 − 0.029
ENST00000255409.8 57.89 93.08 − 35.18 0.111 0.018 0.093 − 0.144
ENST00000272252.4 89.09 99.88 − 10.79 0.079 0.001 0.078 − 4.478
ENST00000222800.4 68.00 93.15 − 25.15 0.110 0.032 0.078 − 0.090
ENST00000382977.11 33.33 100.00 − 66.67 0.073 0.000 0.073 − 0.804
ENST00000389175.23 20.00 64.30 − 44.30 0.113 0.052 0.061 − 0.151
ENST00000265316.3 83.78 97.45 − 13.67 0.079 0.018 0.061 0.053
ENST00000355774.3 89.19 99.93 − 10.75 0.054 0.000 0.054 − 0.379
ENST00000398141.8 10.95 19.95 − 9.00 0.699 0.648 0.052 − 0.640
ENST00000357115.15 90.70 99.74 − 9.04 0.053 0.003 0.051 − 0.570
ENST00000487270.3 92.59 99.68 − 7.08 0.052 0.002 0.050 − 0.251
ENST00000216294.2 92.31 99.55 − 7.24 0.054 0.003 0.050 − 0.150
ENST00000338382.7 91.30 99.77 − 8.47 0.053 0.003 0.050 − 0.559
ENST00000331493.9 9.58 21.35 − 11.77 0.149 0.099 0.050 − 0.203
ENST00000328867.14 69.23 89.54 − 20.31 0.055 0.014 0.041 − 1.237
ENST00000376811.6 89.58 99.50 − 9.91 0.041 0.003 0.037 − 0.092
ENST00000535273.7 83.78 94.41 − 10.62 0.081 0.045 0.036 0.116
ENST00000370132.6 85.45 98.61 − 13.16 0.041 0.008 0.033 − 0.221
ENST00000542534.16 50.00 100.00 − 50.00 0.027 0.000 0.027 − 0.167
ENST00000354366.10 81.82 99.98 − 18.16 0.027 0.000 0.027 − 0.153
ENST00000238561.9 82.35 95.81 − 13.45 0.041 0.015 0.026 0.018
The 30 prime NAS candidates are those supporting an association between the PTC and increased relative exon skipping (PSI < –5), as well as absolute
exon skipping (RPMskip > 0.026), sorted by decreasing RPMskip. Exon ID is defined as ‘ensembl transcript id.exon number’ where the exon number
is incremented in the direction of transcription. logit scores are those predicted by MMSplice. PTCs that also appear in the ClinVar dataset are shown
in bold.
trol cells (P < 0.001, two sample t-tests, Figure 4E), as well
as confirm that NMD is functionally depleted using TCR-
beta reporter constructs (Supplementary Figure S5C) (84).
We also note that experimental PSI and skipped isoform
levels are broadly consistent with our computational PSI
calculations for the 1000 Genomes samples. We find sim-
ilar patterns in Hek293T cells (Supplementary Figure S5)
thus demonstrating PTC-associated exon skipping indepen-
dent of cell type. For full gel images underlying Figure 4, see
Supplementary Figure S6, for those associated with Supple-
mentary Figure S5 see Supplementary Figure S7.
The above validates that our bioinformatic pipeline’s top
hit is a bona fide example of NMD-independent NAS.
While here we are not concerned with the mechanism in this
instance, we suggest that the minigene construct recapitu-
lating what is seen in vivo, provides good raw material for
downstream analysis.
We also sometimes observe a faint third band for the PTC
mutants (Figure 4B, black triangle). However, this is not
seen in both cell types (Supplementary Figure S5) and failed
attempts at replication. We therefore consider it unsafe to
draw any inference from the presence of this band.
Large-effect PTCs are in silico predicted to have larger in-
creases in exon skipping when compared with the other PTCs
The above analysis provides lower bound estimates for the
frequency of PTC-mediated alternative splicing (ca. 4–6%).
As our bounds for inclusion (5% difference) are relatively
weak, this may be considered a generous lower bound, but
as such also suggests that NAS is typically not induced by
polymorphic PTCs. We consider upper bound estimates be-
low when considering ClinVar data. First, however, we fur-
ther analyse the 1000 Genomes data to address the further
two predictions of the motif model.
If NAS is owing to motif disruption, then
motif/nucleotide based inference models should be
able to predict which PTCs are splice disruptive. Note
that the machine learning models are not trained on stop
codons. We predicted changes in PSI for each PTC using
MMSplice (72), a neural network model that outperforms
other splicing variant scoring models (HAL (89), SPANR
(90) and the baseline predictor model MaxEntScan (91)).
MMsplice reports the effect of a variant on PSI on the
logistic scale (logit), with logit < 0 indicating a pre-
dicted increase in exon skipping associated with the variant.
We find 25/30 (83.33%) of our large-effect candidates are
predicted to increase skipping in this model, significantly
more than expected by chance (P = 3.249 × 10–4, two-tailed
exact binomial test). Further, these differences in predicted
skipping are significantly greater than for the remaining 511
variants (median large-effect PTC logit = −0.185, me-
dian other PTC logit = −0.140, P = 0.0242, one-tailed
Wilcoxon rank sum test).
While then NAS can be predicted by sophisticated ma-
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Figure 4. Experimental validation of the top NAS candidate located in the ACP1 gene. (A) Schematic overview of the minigene construct. Exon/intron
lengths are defined below the relative minigene section, with ATG appended to the minigene 5′ terminal to allow for protein translation. The variable site,
position 23 of exon 2 (solid black bar), contained either a C (wt) or T (PTC variant). (B) Agarose gel electrophoresis of RT-PCR of HeLa cells (three
biological replicates each) treated with either a non-targeting siRNA pool control (NTC) or Upf1-targeting siRNA (siUpf1). mKate2 levels are shown as
transfection control. (C) PSI levels for wt and PTC-containing ACP1 variants. Bands corresponding to full-length transcript and transcript with skipped
exon were first normalised to mKate2 before calculating PSI as full-length transcript divided by full-length transcript + transcript with skipped exon (n = 3).
(D) Relative levels of exon skipping are shown as the ratio of normalised levels of transcript with skipped exon in a given condition to the normalised levels
of transcript with skipped exon in the wt NTC control (n = 3). (E) Relative Upf1 mRNA expression levels in Upf1 knockdown and control cells. Error
bars denote the standard error of the mean for 3 biological replicates. Tests are two sample t-tests.
we find no evidence that the 30 NAS associated mutations
are any more likely to disrupt an ESE than the 511 not con-
sidered NAS candidates. Using the INT3 dataset, for ex-
ample, and considering the nucleotides −5 to +5 of the fo-
cal mutation (i.e. allowing the mutation to be anywhere be-
tween the end or beginning of an ESE hexamer), we find
no evidence that the 30 NAS candidates have a higher den-
sity of ESEs in this span than the 511 (Mann−Whitney U
test, P = 0.39). Asking about the number of cases where one
or more ESE is seen overlapping the focal mutational po-
sition, we see no difference between the NAS candidates
(6 with a ESE, 24 without) and others (70 with an ESE,
441 without) (chi squared with Yates’ correction = 0.93,
P = 0.33), although the frequency (20%) is higher for the
former than the latter (13.7%). We also see no correlation
between PSI and the number of ESE motifs associated
with any given span in the proximity of any mutation (spear-
man rank test, rho = 0.005, P = 0.90). We conclude that
presence of ESEs at the site of the mutation is not a good
predictor of which nonsense mutations do or do not induce
NAS in this dataset. The candidate set (N = 30) and the re-
maining exons (N = 511) are no different in ESE density
within an exonic compartment (i.e. 5′ flank ESE density of
the NAS set is no different from 5′ flank density of the non
NAS set etc, Supplementary Figure S8). Employing only
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cover the classical result that exon flanks tend to have higher
ESE density than exon cores (Supplementary Figure S8B).
Out of frame mutations to TAA, TGA or TAG also are asso-
ciated with exon skipping
To further scrutinize the motif model we analysed muta-
tions to TGA, TAA or TAG that are out of frame by
one nucleotide. These we refer to as mutations creating
‘shiftPTCs’. We retain only one mutation per exon and
asked if they were also associated with exon skipping, as
predicted by the motif model.
We performed similar analyses to those above. We find
that the absolute differences in shiftPTC PSI scores between
the variants (shiftPSI) were significantly greater for dif-
ferences consistent with NAS (P < 2.2 × 10–16, one-tailed
Wilcoxon rank sum test, median shiftPSI > 0 = 0.049, me-
dian shiftPSI < 0 = −0.726). Further, we find the same
is true for RPMskip for the shiftPTCs (shiftRPMskip)
(P < 2.2 × 10–16, one-tailed Wilcoxon rank sum test, median
(shiftRPMskip > 0 = 0.011, median (shiftRPMskip < 0
= −3.950 × 10–4).
218/6948 exons exceed the large-effect PSI threshold
(>5%), with a significantly greater number showing de-
creased PSI in the shiftPTC−/+ than for the shiftPTC−/−
variants (171/218, P < 2.2 × 10–16, one-tailed exact bino-
mial test, see Supplementary Figure S9A). Further, 183/218
(83.94%) cases have shiftRPMskip > 0 consistent with
NAS (using the threshold of 0.04871, this being the cut-off
to size match the 218 PSI variants), a significant number
(P < 2.2 × 10–16, one-tailed exact binomial test, see Supple-
mentary Figure S9B). 100/218 (1.44% of total shiftPTCs)
of these shifted PTCs have greater than 5% difference for
both PSI and RPMskip. The number of large-effect cases
is significantly lower than for those in-frame ( 2 = 47.231,
P = 6.309 × 10–12, chi-squared test). However, simulations
picking 171 and 183 cases at random suggest the 100 large-
effect cases with both PSI and RPMskip in the direction
consistent with NAS is more than expected by chance
(P ≈ 9.999 × 10–5, one-tailed empirical P-value).
As out of frame mutations to TAA, TGA or TAG would
not be subjected to NMD, the above result provides fur-
ther evidence to suggest that NMD cannot explain all of the
previous differences in exon inclusion we observe between
genotypes.
Enrichment analysis predicts that about a third of pathogenic
nonsense mutations may have their effect via splicing
PTCs associated with disease phenotypes are expected to
be enriched for cases of NAS and thus provide a means
to estimate an upper bound for the rate at which PTCs
disrupt splicing. Here our method is more indirect. We
ask about the extent of end of exon enrichment of known
disease-associated nonsense mutations (similar to (71)), as
splice modifying mutations are enriched towards exons ends
(49), where ESEs, other splice signals and splice disrupt-
ing mutations typically reside (48,49,52–54,92,93). We also
ask whether the end-of-exon PTCs are likely to be splice-
modulating by looking for ESE enrichment and via in silico
prediction.
We assume exonic core pathogenic nonsense mutations
(beyond both the 5′ and 3′ terminal 69 nucleotides) not to
have a major effects on splicing (48). Their rate thus pro-
vides us with a background level (although is likely conser-
vative as splice-affecting mutations also occur in exon cores
(49)). Any excess of pathogenic nonsense mutations above
this core level we then assume to be splice-related. This is
also a strongly indicative metric as enrichment at exon ends
isn’t obviously expected by alternative mechanistic mod-
els (NMD and protein truncation). Indeed, if anything, as
NMD cannot detect some PTCs towards the end of the
last but one exon (94), NMD based mechanisms might pre-
dict weak enrichment away from exon ends. Moreover, with
lower SNP levels at exon ends (48) in healthy individuals,
any enrichment in PTCs is unlikely to have a mutational ex-
planation.
Using a set of disease-associated mutations from the
ClinVar dataset (70), we find both ‘pathogenic’ and ‘likely
pathogenic’ variants occur in exon flanking regions more
frequently than expected by chance (see Supplementary
Text S5). Taking the coding exons in which pathogenic non-
sense mutations occur (N = 3,572), we define the exon core
as any nucleotide beyond the terminal exon 69 nucleotides,
this being the approximate upper range of ESE activity (48),
although some ESEs show constraint past this (57) and a
few are functional in exon cores (95). We observe 1,804 non-
sense mutations within the 321 918 nucleotides of exon cores
at a rate of 0.0056 mutations per nucleotide. Thus, assuming
exon flanks behave like exon cores we expect ≈ 2365 non-
sense mutations in the 422 017 exon flank nucleotides. In-
stead, we observe 4447, an excess of 2082 (32.77%) of mu-
tations (see Supplementary Spreadsheet S4). This suggests
that in regions with an increased density of splice informa-
tion, pathogenic nonsense mutations occur much more fre-
quently than expected. The effect of likely pathogenic muta-
tions appears stronger with an excess of 58.49% of nonsense
mutations in exon flanks (see Supplementary Spreadsheet
S4).
The above estimate is higher than a more conservative es-
timate of 10% of all mutations that cause disease by splice
disruption. As this required both in vitro and in vivo verifi-
cation of splice disruption (67) this is to be expected. Our
estimate is in line with enrichment analyses similar to ours
that estimate a third of all disease-associated mutations to
modulate splicing (62,71), but is higher than an early esti-
mate of circa 15% (96) that considered only mutations in the
immediate vicinity of splice sites (see also 97).
Disease-associated PTCs are disproportionately embedded in
ESEs
Despite this biased ‘end of exon’ distribution, pathogenic
nonsense mutations may not disrupt splicing. As the
strongest signal of selection on splice motifs is on ESEs, as
opposed to ESSs (55), we asked whether pathogenic muta-
tions disrupt ESEs more than expected by chance. Specifi-
cally, we determined whether the pathogenic nonsense mu-
tations hit one of the INT3 ESEs (52) in the exon flank re-
gions more frequently than reference allele-matched simu-
lants (N.B. INT3 is a low false positive set of ESE motifs ob-
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this to be the case (Z = 9.555, P ≈ 9.99 × 10–5, one-tailed
empirical P-value, Figure 5). ‘Likely-pathogenic’ mutations
also hit ESEs within the exon flanks more frequently than
expected (Z = 5.877, P ≈ 9.99 × 10–5, one-tailed empirical
P-value) although the effect is weaker than for the well-
characterised pathogenic variants. The same is not seen for
the PTC variants in 1000 Genomes data (above and Figure
5).
However, simulated mutations occur less frequently than
true nonsense mutations in the 3–69 nucleotide region (see
Supplementary Text S5). Therefore, for each pathogenic
nonsense mutation in the 3–69 nucleotide exon region we
randomly picked a nucleotide-matched pseudo-nonsense
mutation (not generating a PTC in the ClinVar dataset)
also from within the 3–69 nucleotide region. Again, the real
nonsense disease-associated mutations hit ESEs more fre-
quently than expected (Z = 1.920, P ≈ 0.030, one-tailed em-
pirical P-value).
These results indicate that disease-associated nonsense
mutations are distributed non-randomly in exons and hit
ESEs more frequently than expected after control for muta-
tional frequency (between exons and across the same exon),
underlying nucleotide content of the 3–69 nucleotide region
and relative expression (simulations are within the same
exon). Moreover, pathogenic PTCs occur in non-3n exons
more frequently when the exon is relatively long, with exons
containing pathogenic PTCs typically having higher ESE
density (Supplementary Text S6).
In silico prediction supports a role for some disease-
associated PTCs in splice modulation
Above we have considered one class of motif known to
modulate splicing. We can also ask whether, more gener-
ally, machine learning approaches also predict splice dis-
ruption. We find that 82.75% (5258/6354) of variants had
a negative effect on computationally predicted PSI, a sig-
nificantly greater number than expected simply by chance
(P < 2.2 × 10–16, one-tailed exact binomial test, null prob-
ability of success = 0.5). This effect is slightly more pro-
nounced for variants occurring in exon flanks (3722/4447
(83.70%), P < 2.2 × 10–16, one-tailed exact binomial test,
null probability of success = 0.5) but not significantly so
( 2 = 1.603, P = 0.206, chi-squared test), suggesting that
pathogenic nonsense mutations in exon cores also fre-
quently disrupt splicing, as described in minigene con-
structs (95).
The above result is, however, confounded by the fact that
‘short’ exons (those less than 138 bp) are all exon ‘flank’ in
the sense that ESEs function up to ≈69 bp from an exon
end (48). When restricting the analysis to only those ex-
ons longer than 138 bp, we find that although pathogenic
nonsense mutations reduce PSI more than expected in both
the exon flanks (1938/2327 (83.28%), P < 2.2 × 10–16, one-
tailed exact binomial test, null probability of success = 0.5)
and exon cores (1454/1804 (80.59%), P < 2.2 × 10–16, one-
tailed exact binomial test, null probability of success = 0.5),
the difference in the relative number of mutations decreas-
ing PSI between the two regions is significant ( 2 = 4.805,
P = 0.028, chi-squared test). Thus, our previous estimate of
the number of pathogenic nonsense mutations disrupting
splicing based on the core rate is likely conservative. We find
a similar number of likely-pathogenic mutations decrease
PSI (906/1075 = 84.28%), P < 2.2 × 10–16, one-tailed exact
binomial test, null probability of success = 0.5).
Taken together with the excess in ESE flanking regions,
it is reasonable to assume that splice disruption and exon
skipping attributable to PTCs is likely to be a quite frequent
source of pathogenicity.
DISCUSSION
We considered the viability of the motif model to explain
why PTCs can be associated with splicing disruption (NAS).
A priori we reasoned that the motif model is parsimonious,
not least because exonic regulatory splice motifs, such as
ESEs, must and do, contain few stop codons (40). Exonic
splice motifs may therefore be particularly sensitive to mu-
tations creating TAA, TGA or TAG trinucleotides, includ-
ing those out of frame.
The motif model makes a fairly robust account of the
data. First, splice disruption associated with PTCs is not
associated with all PTCs but just a limited subset (∼5% in
non-disease data and ∼30% in disease associated PTCs). A
midway estimate is roughly in agreement with analyses of
random mutations (not PTCs) in minigene exons, which,
after exon size correction suggests a similar figure for the
proportion of mutations that disrupt splicing (58).
Second, the motif model predicts which subset of PTCs
initiate NAS. We found that NAS presence/absence in 1000
Genomes data can be predicted from motif centred infor-
mation, the machine learning motif recognition methods
being trained predominantly in the absence of in-frame stop
codons on splice patterns of exons. However, the skipping
events seen in the 1000 genome data seem rather uncoupled
from ESE mediated events suggesting that it is other motifs
that the machine learning approaches identify. By contrast,
enrichment of disease associated PTCs at exon ends and in
ESEs is supportive both of the motif model and involve-
ment of ESEs in particular. Third, that NAS is also seen in
the out of frame context is supportive of the motif model.
The relevance of the data for the scanning model
We have not considered the scanning model in detail and the
sort of data that we analyse has rather little power to scru-
tinise it. It is not obvious that it makes predictions about
the commonality of NAS (test 1). It also makes no strong
claims (that we are aware of) regarding any motifs in the
vicinity of the PTC that might induce scanning mediated
NAS (test 2). That we find out of frame TAA, TGA and
TAG mutations induce NAS would argue that some pro-
portion of NAS cannot be explained by frame-dependent
scanning (test 3).
While the data provide support for the motif model, they
do not, however, falsify the scanning model. As the two
models are not mutually exclusive, it is possible that some
NAS is associated with scanning, for example for PTCs
that aren’t embedded within splicing motifs and that are in
frame. The fact that we see a difference between the rate of
splicing disruption associated with in-frame nonsense mu-
tations and out of frame TAA, TGA and TAG mutations is
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Figure 5. Frequencies of ESE nucleotides hit by PTCs in respective exon regions. Z scores comparing how frequently pathogenic and likely pathogenic
variants from the ClinVar data set and variants in the 1000 Genomes dataset hit ESE motifs when compared with 10 000 randomly sampled nucleotides
matching the reference-allele of the nonsense mutation SNP variant. Pathogenic and likely pathogenic variants hit ESEs significantly more frequently than
expected (P ≈ 9.99 × 10–5 in both cases), although the enrichment over expected is stronger for pathogenic variants. Consistent with the non-exceptionality
of the 1000 Genomes variants, these do not hit ESEs more frequently than expected in any region when compared with the randomly sampled variants.
Is NMD a confounding variable?
Can we be confident that NMD hasn’t interfered with anal-
yses? The RPMskip data, analysis of out of frame stop
codons and experimental data examining skipping in the
absence of NMD, all argue against NMD as the cause of the
effects that we see. It is also notable that without looking at
the absolute PSI values or correcting for nucleotide com-
position, we did not observe PTCs to associate with lower
PSI. This is surprising given that such an association would
be expected purely because of NMD downregulation of the
full-length isoform, even if no NAS is occurring. One ex-
planation could be that NMD is very weak in our samples.
However, the large and highly significant decrease in RP-
Minclude in PTC−/+ samples argues against this scenario.
Alternatively, it is possible that the mutations either create
ESEs or disrupt ESSs leading to a slight increase in exon
inclusion. A more likely explanation is that, at least for the
exons being considered, splicing is very precise and, in most
cases, no detectable exon skipping is observed. Indeed, the
median PSI overall for PTC−/− samples is ≈ 99.994% and
median PSI ≈ 0.
Are our estimates good upper and lower bound estimates?
Are we correct in thinking that our PTC/NAS rate esti-
mates from ClinVar and 1000 Genomes data really repre-
sent upper and lower bounds? In both cases, the estimates
either replicable (as we have shown) or comparable to prior
similar estimates (see results). We also attempted to confirm
the 4–6% lower bound using a third independent dataset
(98) but this was not large enough to report meaningful in-
formation.
The lower bound estimate will be sensitive to the thresh-
old employed to define NAS. As we make the cut-off more
stringent, so naturally fewer PTCs would be classified as
NAS associated (Figure 3A). However, while the 5% cut-
off is somewhat arbitrary, many PTCs are associated with
much stronger effects (Figure 3A). Whether it is 2% (more
stringent) or 6% that are seen to affect splicing is rather ir-
relevant in the current context, as we are simply attempting
to estimate lower bounds and these numbers are all to a first
approximation congruent. The point of using a low thresh-
old in the first place was to establish whether, with a possibly
relaxed threshold, the great majority of PTCs are associated
with splice disruption, which would not be consistent with
the minigene experiments (58) after control for exon length
effects.
We can also ask whether other evidence supports the pre-
sumed ascertainment biases affecting both estimates. One
likely reason for the difference between the two estimates is a
difference in selection acting on the two classes of PTC ow-
ing to sampling: under-estimating in the lower bound, over-
estimating in the upper bound. As expected with such ascer-
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flanking regions on nonsense mutations in the 1000 genome
data, while in the ClinVar dataset we see a significant excess
(see Supplementary Figure S10). These results are consis-
tent with purifying selection acting especially strongly on
mutations at exons ends (within 69 bp of the junction) and
argues against a null of differential mutation rates across the
exon. This strongly supports the notion that the two sam-
ples are likely to be affected by opposite ascertainment bi-
ases.
A further factor, aside for ascertainment biases, could be
that our filtering process is likely to have excluded large-
effect cases in genes that are lowly expressed (and there-
fore not considered due to few individuals with quantifiable
splicing). We find no evidence to suggest that allele frequen-
cies of the large effect variants are greater or less than for the
other variants (P ≈ 0.200, one-tailed empirical P-value).
While we presume that our set of PTCs that are poly-
morphic in 1000 Genomes data are on average of lower fit-
ness effects than those seen in ClinVar data, this need not
be true for all 1000 Genomes PTCs. The literature contains
several examples where our large-effect cases have been as-
sociated with disease. For example, the transcript with the
largest PSI difference, ENST00000409520, is encoded by
the TraB domain containing 2A (TRABD2A) gene associ-
ated with negative regulation of the Wnt signalling path-
way, itself heavily implicated in cancers (99–105). Further,
mutations in the NDUFV2 gene producing the transcript
ENST00000400033 have been associated with Parkinson’s
(106) and Leigh syndrome (107). Mutations in our prime
candidate ACP1 (ENST00000272065) have been associ-
ated with diabetes (108,109). Five cases also overlap with
the disease-associated mutations in the ClinVar database
(rs62624965, rs202001274, rs148458820, rs200355697 and
rs74103423 (Table 1 bold, Table 2)). Whether NAS is the
mode of operation in these instances we leave to future
study.
Skipping versus other modes of splice disruption
Exon skipping is the most common type of alternative splic-
ing in wild type state in humans (66), in response to mu-
tation (67) and associated with CRISPR generated indels
(68,69) (many of which may be incidences of NAS). The
commonality of skipping is extremely beneficial for this
analysis as some modes of our analysis (transcriptomics)
address skipping exclusively, while other modes (e.g. k-mer
enrichment) are blind to the exact mode of splice disruption.
As a consequence, to make the upper and lower bound es-
timates strictly comparable they would need to be rescaled.
For example, as the lower bound 6% figure pertains to skip-
ping alone, then to be directly comparable to the upper
bound, and to the meta-analysis of minigene splicing dis-
ruption, this figure would need to be scaled up (or the other
estimates scaled down). Given the relative commonality of
skipping this we assume to be a relatively minor adjustment.
Indeed, it probably brings the lower bound estimate in to
line with the lower bound of the meta-analysis estimate, al-
though given sensitivity to threshold cut-offs we ascribe lit-
tle to this.
It is not unreasonable to suppose that nonsense muta-
tions might act via modes other than exon skipping. Splice
site creation may indeed, a priori, be a possible mode of ac-
tion. The 5′ and 3′ splice site consensus motif AG|GT of
U2 introns could be generated from a nonsense mutation
of the sequence TA[C\T]GT via a C or T to G mutation
at site three. Further, G|A can define rarely used U12 splice
sites and hence appear as [C\G\A]GA→TGA mutations.
Other modes are imaginable. A nonsense mutation could,
for example, create an exonic splicing silencer (ESS) (a cis-
regulatory element that inhibits the use of adjacent splice
sites (110)) or modulate RNA structure (15), which may
in turn modulate motif accessibility. One reason we chose
not to consider ESSs was owing to a lack of certainty con-
cerning their identity. In particular, prior analyses (55) de-
tected no evidence for selection operating on the candidate
(110) ESS motifs when in exons. The motifs also don’t show
avoidance of stop codons, despite CDS exonic motifs be-
ing motifs that should (by definition) have low stop codon
density (40,50).
NAS is unlikely to be an evolutionarily conserved error-
proofing mechanism to rescue PTC-containing transcripts
NMD is commonly thought of as an evolved mechanism to
protect against ‘unwanted’ transcripts by recognizing that
they contain premature stop codons. However, NMD might
itself be the source of problems by reducing the dosage.
Could NAS be an evolved quality control mechanism to
prevent NMD operating on a particular subclass of genes?
In some of the language concerning the scanning model in
particular, a possible adaptive significance seems to be im-
plicit. For example, Cartegni et al. (15) suggest that the pro-
cess is there to verify the integrity of an ORF and, ‘when
necessary, direct the splicing machinery to skip the offend-
ing exon’ (15). Wang et al (37) similarly refer to it as a ‘cor-
rection response’.
In many cases, the phenotypic consequences of splic-
ing out an exon containing what would be a PTC should
be less harmful than either degradation of the transcript
or truncation of the protein, particularly if exon skipping
maintains reading frame integrity. In this scenario, there
could conceivably be selection for NAS. For example, non-
sense mutations in the dystrophin-encoding DMD gene re-
sult in loss of functional protein (111) resulting in Duchenne
muscular dystrophy (DMD). However, in Becker muscu-
lar dystrophy (BMD), which has a less severe phenotype
(21,22,112–116), the PTC results in NAS encoding a short-
ened transcript but retaining the reading frame, restoring
partial protein functionality. Similarly, the ability to ex-
press functional, yet shortened isoforms, such as CEP290
exon-skipped isoforms, is correlated with disease severity
(16–19).
However, NAS also affects exons that are not multiples of
three long, and as we find, these often being pathogenic vari-
ants. Moreover, we find no evidence to suggest that PTCs
associated with NAS in a ‘healthy’ context occur predom-
inantly in exons of length 3n (see Supplementary Text S7).
Given the relative rates of large-effect NAS, and that much
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Table 2. Further information regarding the five prime NAS candidates overlapping ClinVar variants
PTC ID Exon ID Mutation Information
rs62624965 ENST00000367409.18 T > G • ASPM gene.
• Benign mutation (70).
• ASPM produces two isoforms, one with exon 18 skipped, in both
human and mouse and therefore may encode two proteins with different
functions (133), thus skipping of exon 18 may not be as detrimental.
rs202001274 ENST00000456763.12 C > T • MAPKBP1 gene.
• Associated with Nephronophthisis 20 (134).
• Homozygous PTC Individual produced full-length and exon-skipped
isoforms.
• Thought to affect binding of serine-arginine rich (SR) protein SF2/ASF
binding leading to exon skipped isoforms.
rs148458820 ENST00000265316.3 G > A • ABCB6 gene.
• Mitochondrial porphyrin transporter essential for heme biosynthesis.
• Associated with Langereis blood group (135).
• May have implications in blood transfusions and drug therapies (136).
• ABCB6 also thought to contribute to anticancer drug resistance (137).
rs200355697 ENST00000487270.3 C > T • RAD51B gene.
• Encodes a DNA repair protein.
• Uncertain significance for hereditary cancer-predisposing syndrome.
• RAD51B splice mutations leading to exon skipping have been associated
with cancer (138).
rs74103423 ENST00000370132.6 G > T • Dihydrolipoamide branched chain transacylase E2 gene.
• Associated with maple syrup urine disease (MSUD) (139).
Truncated and exon skipped isoforms found.
Exon ID is defined as ‘ensembl transcript id.exon number’ where the exon number is incremented in the direction of transcription.
very small and likely a reflection of stochastic variation in
exon inclusion, it seems unlikely that NAS is a genome-wide
error-proofing mechanism under selection to rescue tran-
scripts from NMD. Further, fitness benefits associated with
the small variations in exon skipping PTCs are unlikely to
be selectable. If PTC-containing transcripts derived from in-
herited mutations are particularly costly to fitness, the PTC-
containing allele would likely be eliminated via purifying se-
lection (although in rare and very specific cases variants are
advantageous (117–119)). Thus, NAS is unlikely to be an
evolutionarily conserved adaptive mechanism.
Our results are consistent with the alternative model,
namely that NAS occurs as a consequence of ESE-binding
proteins having to recognise a set of motifs that, due to be-
ing located within exons, by definition have a depletion of
stop codons (40,67). Nonsense mutations thus break such
interactions and cause unwanted splice disruption. How-
ever, this leaves unanswered the problem of why some non-
sense mutations appear to be reading frame dependent in
their ability to induce skipping (26). It could also be ques-
tioned why our prime candidates from 1000 Genomes data
are not seen to hit ESEs more frequently. As we used a con-
servative set of ESEs it is possible that other motifs also
function as splice enhancers but are not included in our
set of motifs. Indeed, it could be that ‘weak’ motifs are as-
sociated with the weak NAS effects that we witness in the
1000 genome data, while ‘strong’ motifs cause more severe
disruption and are thus associated with pathogenic effects.
That the machine learning approaches find enrichment of
splice defects in the 1000 genome NAS associated PTCs
supports such a more nuanced model.
The importance of accurate classification of nonsense muta-
tions and their roles in therapeutics
Our results demonstrate the importance of understanding
the broader implications for the classification of mutations.
Even our conservative estimate suggests that the pathogenic
effects of a significant proportion of nonsense mutations
could be misunderstood. This data provides further evi-
dence to suggest mutations in general, but SNPs in par-
ticular, should be routinely analysed at the mRNA level
(15) prior to classification as mutations with seemingly no
functional significance can be deleterious (120,121). This
is particularly applicable to synonymous mutations, whose
pathogenic significance might otherwise be overlooked -
such mutations may disrupt ESEs or even create cryptic
splice sites that result in a diseased phenotype (122–124) de-
spite having no direct effect on the peptide sequence.
The consequences of correct classification of nonsense
mutations might be best contextualised when consider-
ing therapeutic approaches to disease. A variety of ther-
apies targeting nonsense mutations have been shown to
restore protein function (125,126), however, these thera-
pies are only effective if the PTC is present in the ma-
ture transcript. For example, a variety of diseases includ-
ing Mucopolysaccharidosis type VI (MPS VI) (127), Usher
syndrome (128,129) and DMD (130,131) are treated us-
ing strategies involving PTC124. This is thought to sup-
press translation termination at PTCs but not natural stop
codons (132) and is therefore only effective if substantial
levels of mRNA are available containing the PTC. However,
if the PTC disrupts splicing and leads to exon skipping any
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